Quality control samples were selleck chemical prepared in blank plasma at low, medium and high concentration of the calibration curve. Acceptance criteria

based on current guidelines were used for each analytical batch. Batches not meeting these acceptance criteria were rejected and the samples repeated. 2.4 Treatments Schedule Subjects received the investigational products—doxylamine hydrogen succinate 12.5 mg Lonafarnib (Dormidina® 12.5-mg film-coated tablets, Laboratorios del Dr. Esteve, S.A, Barcelona, Spain) or doxylamine hydrogen succinate 25 mg (Dormidina® 25-mg film-coated tablets, Laboratorios del Dr. Esteve, S.A, Barcelona, Spain)—at each period of the study under fasting conditions according to the randomization list. The randomization scheme was computer generated. Food was controlled and standardized during the housing period and for all subjects. Subjects fasted overnight for at least 10 h prior to drug administration. A single dose of the Investigational Product was thereafter administered orally with approximately 240 mL of water at ambient temperature. Fasting continued for at least 4 h following drug administration, after which a standardized lunch was served. A supper and a light snack were also served at appropriate times thereafter, but not before 9 h after dosing.

Water was allowed ad libitum until 1 h pre-dose and beginning 1 h from drug administration. 2.5 Statistical Analysis 2.5.1 Sample Size Based on the result of a previous study, the intra-subject Androgen Receptor antagonist variability of AUC t for this product is around 6.2 % [6]. Assuming the expected geometric mean ratio of dose-normalized AUC t is within 95–115 %, to meet the 80–125 % bioequivalence range with a statistical power of at least 80 %, it is estimated that the minimum number

of subjects required is 6. On the other hand, the minimum number of subjects for a standard bioequivalence study according to EMA’s guideline is 12. Therefore, it should be sufficient for this study to include 12 healthy volunteers. 2.5.2 Statistical Comparison Descriptive statistics were used to summarize adverse events, safety results and demographic variables (age, height, weight PD184352 (CI-1040) and BMI). Pharmacokinetic parameters such as C max, the time to reach C max (t max), AUC t , AUC ∞ , AUC t :AUC ∞ , the elimination rate constant (k e) and elimination half-life (t ½) were calculated for each strength tested. According to EMA’s Guideline on the Investigation of Bioequivalence [8], dose proportionality in terms of extent of exposure was assessed based on the parameter AUC t normalized (i.e. dose-adjusted AUC t ). Moreover, dose proportionality in terms of rate of exposure was also assessed using the parameter C max normalized. The natural logarithmic transformation of AUC t was used for all statistical inference using an Analysis of Variance (ANOVA) model.